drugset / Trial / NCT06438263

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

NCT06438263

Phase 1 Completed 231 enrolled Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.

Timeline

Start
2024-08-06
Primary completion
2025-05-03
Completion
2025-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocatinlimab Monoclonal antibody Subcutaneous

Indications